Tesamorelin
FDA-approved GHRH analog that reduces visceral fat and stimulates GH release
Clinical Research Score: 5/5 — FDA-approved as Egrifta, with randomized clinical trials demonstrating reduction of visceral fat in HIV-associated lipodystrophy.
Categories: Weight Loss / Metabolic, Hormonal Support
What is Tesamorelin?
Tesamorelin has a distinction most peptides can't claim: it's FDA-approved. It was originally developed to reduce the dangerous visceral fat that accumulates in certain conditions, but the broader wellness community took notice because it attacks the most stubborn and health-damaging type of fat there is — the deep belly fat that wraps around your organs.
People report a noticeable reduction in waist circumference, improved body composition, and a gradual leaning-out effect. Sleep improves. Energy increases. But unlike exogenous growth hormone (which comes with a laundry list of side effects), Tesamorelin works by stimulating your own pituitary to produce GH naturally.
The clinical evidence here is robust. Published studies show significant reduction in visceral fat and improvements in lipid profiles. For people specifically targeting dangerous abdominal fat — not just subcutaneous padding, but the metabolically active deep fat — Tesamorelin is one of the most evidence-backed options available.
How Tesamorelin works
Tesamorelin is a synthetic version of your body's own growth hormone releasing hormone (GHRH). It stimulates the pituitary gland to produce and release growth hormone in its natural pulsatile pattern — the same rhythm your body used when you were younger. This elevated GH increases IGF-1 levels, which in turn accelerates fat metabolism, particularly targeting visceral (deep abdominal) fat. Because it works through natural feedback mechanisms, it's less likely to cause the excessive GH levels and side effects associated with direct HGH injection.
Scientific overview
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that has been FDA-approved for the treatment of HIV-associated lipodystrophy. It stimulates the pituitary gland to produce and release growth hormone in a physiological pulsatile pattern. Studies have shown significant reduction in visceral adipose tissue and improvements in lipid profiles.
Dosing
- Starting dose: 1 mg per day
- Common dosage range: 1-2 mg per day for 8-12 week cycles
- Administration: Subcutaneous
- Half-life: ~26 minutes
- Frequency: 1x daily for 8-12 week cycles (typically followed by a 4-week break)